Innate Pharma eprorts €2.6M Q1 revenue, maintains cash runway to end-Q3 2026
Innate Pharma (NASDAQ:IPHA), a clinical-stage biotechnology company specializing in immuno-oncology, announced its business update and consolidated financial results for the quarter ended March 31, 2026.










